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Summary
Tumour necrosis factor (TNF)-a is crucial for resistance to Trypanosoma
cruzi acute infection, but there is scant information on its role during the
chronic phase. To address this issue, we analysed whether a short treatment
with a TNF-a blocker affected the course and characteristics of chronic
disease in a rat experimental model of T. cruzi infection.An anti-TNF-a agent
(infliximab) was administered during the chronic phase for a period of 4
weeks (3 mg/kg/week), while control infected rats were inoculated with saline
physiological solution. Search for parasites yielded non-successful results in
all infected groups, irrespective of treatment. Nevertheless, the presence of T.
cruzi kDNA in heart tissue was detected in infected and infected plus treated
animals. Because infliximab might induce changes in the anti-parasite cytok-
ine response, circulating levels of interleukin (IL)-10, interferon-gamma and
nitric oxide were evaluated. An increase in IL-10 levels was observed only in
the infected group treated with the anti-TNF-a blocker compared to the
remaining groups (P < 0·05). A clear attenuation of histological damage asso-
ciated with a diminution of cardiac TNF-amRNA expression was observed in
the infected and treated animals compared to the infected and non-treated
group. Blocking of TNF-a during a relatively short period in chronically
infected rats did not lead to evident parasite reactivation but reduced myo-
carditis severity significantly, indicating a role of this cytokine in the patho-
genesis of chronic myocardial damage.
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Introduction
Chagas’ disease, caused by the protozoan Trypanosoma cruzi,
is one of the most important endemic parasitoses in Latin
America [1]. Acute infection is usually oligosymptomatic
and, once resolved, evolves to an indeterminate and/or
chronic form of disease. The most important clinical mani-
festation of Chagas’ disease is chronic myocarditis, which
affects 30% of infected individuals [2,3]. So far, the factors
underlying distinct clinical outcomes are not understood
completely. However, there is a general consensus that the
cytokine-mediated immune response plays an essential role
both in protection and disease pathogenesis [4,5]. Tumour
necrosis factor (TNF)-a has been identified as one of the
cytokines playing important and opposite roles during
Chagas’ disease. During acute T. cruzi infection, several
studies demonstrate an essential role of TNF-a in the host
defence, triggering phagocytic macrophage activation and
inflammation [6,7]. At the same time, elevated TNF-a levels
are correlated with pathology, including excessive inflamma-
tion, cachexia and death [8–11]. Neutralization of TNF-a or
abrogation of its functionality during acute phase results in
increased parasite burden, ameliorated cachexia and reduced
myocardial inflammatory infiltrates [11]. Because TNF-a
appears to be involved in the development of immunoglo-
bulin (Ig)G antibody response, a deficient humoral response
may account partly for the impaired parasite control seen in
mice devoid of TNF-a effects [12].
In the lifelong chronic phase, histological and/or molecu-
lar techniques show T. cruzi derived-antigens or parasite per-
sistence and inflammatory response of variable severity in
diverse host tissues. Human chagasic myocarditis appears to
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be associated with a low parasite load [13,14] and increased
presence of TNF-a [15,16], suggesting that a persistent
stimulus may induce TNF-a synthesis, favouring control of
subclinical infection, but at the same time the development
of a pathological response. The nature of the stimulus may
be due to the presence of the parasite, its antigens or mimetic
parasite antigens [17].
The role of TNF-a during the chronic phase has been
studied much less. Human studies only show an association
between TNF-a levels and severity of pathology [15,16].
Experimental studies in TNF-a or TNF-receptor (TNF-R)
knock-out animals are not feasible, as they die during the
acute phase. In view of the protective and pathological roles
of TNF-a, the question arises of whether treatment with
monoclonal antibodies against TNF-a, once the acute infec-
tion is resolved, will affect the long-term outcome of this
trypanosomiasis. Besides its intrinsic value, the question is
clinically relevant. Approximately 20 million people are
infected with T. cruzi, for which the potential consequences
of anti-TNF-a therapy in infected individuals presenting
co-morbidities suitable for this intervention need to be
investigated.
To address this issue, we carried out a study in a well-
characterized rat model of chronic chagasic infection devel-
oped in our laboratory [18–21]. In this model, challenge
with T. cruzi in inbred strain ‘l’ rats results in a self-resolving
acute phase followed by a chronic infection in which most
rats develop a mild to intense focal myocarditis [18–21]. The
data indicate that short TNF-a blocking during the chronic
phase did not produce patent T. cruzi reactivation but
reduced myocarditis severity significantly; the hallmark of
Chagas’ disease.
Materials and methods
Rats and experimental infection
Male ‘l’ rats were bred at the animal facilities from the School
of Medicine of Rosario. Animals were housed under a 12-h
light/12-h dark schedule (lights on starting at 07:00 h) with
free access to food and water. All animal procedures were
carried out in accordance with the institutional guidelines.
Young animals (3 weeks old) were injected subcutaneously
with 106 viable trypomastigotes of T. cruzi (Tulahuén strain).
Parasites were maintained by serial passages in BALB/c
suckling mice.
Verification of infliximab bioactivity in ‘l’ rats
The anti-TNF-a chimeric monoclonal antibody, infliximab
(Remicade; Shering Plough, Heist-op-den-Berg, Belgium),
was employed for neutralizing TNF-a. To validate its neu-
tralizing activity, ad-hoc experiments were carried out. First,
two groups of acutely infected young rats were treated
with infliximab (3 mg/kg, three times for 1 week) by the
intraperitoneal (i.p.) route or physiological saline solution,
respectively, beginning 1 day after infection. An additional
control group was inoculated with infliximab at the same
time-points. Parasite circulating load was evaluated until
10 days post-infection (p.i.) by direct microscopic blood
observation. Secondly, two groups of young rats were
injected with a lethal dose of lipopolysaccharide (LPS)
(5 mg/kg); one group was inoculated simultaneously with a
single dose of infliximab (5 mg/kg, i.p.) and the other group
with physiological saline solution (0·1 ml, i.p.). As an addi-
tional control, one group of rats received only infliximab.
Mortality was evaluated for 7 days.
Treatment groups and study design
Young male rats were separated randomly into four groups:
controls non-infected (Co); non-infected but treated with
the anti-TNF-a blocking antibody (infliximab); infected
(Tc); and infected and treated with the anti-TNF-a blocking
antibody (Tc + infliximab). In this model, circulating para-
sites disappear 30 days p.i. resulting in the end of the acute
phase, with chronic myocardial lesions being well established
(or starting to be noticeable) following 10 weeks of infection
[18]. Infliximab administration was initiated after 12 weeks
p.i. (3 mg/kg; three times a week, i.p.) for 4 consecutive
weeks. Co and Tc groups were inoculated with physiological
saline at the same time. Infliximab was found to have a
half-life of 11 days in rats following a dose of 8 mg/kg [22],
for which the 3 mg/kg administered for nearly 48 h is likely
to be highly efficacious in neutralizing endogenous TNF-a.
On completion of the experiments (120 days p.i.), rats
were anaesthetized with ketamine/xylazine, blood was col-
lected by cardiac puncture and serum was stored at -20°C
for further assessment of TNF-a, interferon (IFN)-g, inter-
leukin (IL)-10 and nitric oxide (NO)-derived metabolites
and specific antibody levels. Different tissues were removed
for histopathology.
Parasitological tests
Different approaches were undertaken to detect bloodstream
forms of T. cruzi. First, parasitaemia was assessed by direct
standardized microscopic observation of 5 ml of heparinized
tail venous blood, either before (90 days p.i.) or following
infliximab treatment (120 days p.i.). Data were expressed as
positive (+) or negative (-) samples or parasites/ml when
applicable (400¥ magnification). Following infliximab treat-
ment and to corroborate the presence or not of parasites in
circulation, blood from each infected rat (treated or non-
treated) was inoculated into five highly susceptible newborn
mice (30 ml of blood/mice). After transference, mice were
inspected for mortality and searched for the presence of
trypomastigotes throughout a 30-day period. Xenodiagnosis
of infected rats was also assessed as described previously
after only infliximab treatment [23].
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Polymerase chain reaction (PCR) for identification of
kDNA from T. cruzi
A standard PCR procedure was used, following strict decon-
tamination procedures and the use of disposable material.
The method was used on either blood or tissue samples. Two
hundred ml of blood were obtained from the tail of each rat,
before and after infliximab treatment. Blood samples were
transferred to guanidine–ethylenediamine tetraacetic acid
(EDTA)-containing tubes, boiled for 15 min and stored at
4°C until DNA extraction. After treatment with the TNF-a
blocker, small fragments of fresh heart were collected and
homogenized in a glass tissue grinder. The samples were
mixed thoroughly with guanidine–EDTA, boiled and stored
at 4°C. DNA was extracted by using phenol–chloroform–
isoamyl alcohol followed by ethanol precipitation. Finally,
the solution was suspended in free-endonuclease sterile
water. DNA amplification was carried out in 50 ml of a
mixture containing Taq buffer, 4 mM MgCl2, 0·2 mM of
each deoxynucleoside triphosphate, 1·25 U Taq polymerase
(Fermentas, Hanover, MD, USA) and 1 mM of each primer
(Operon, Köln, Germany). Amplifications comprised a
sequence of 330 base pairs (bp), a T. cruzi-specific repetitive
minicircle sequence (forward primer #121: 5′-AAATAATG
TACGGG(G/T)GAGATGCATGA-3′; reverse primer #122:
5′-GGTTCGATTGGGGTTGGTGTAATATA-3′) [24]. The
PCR reaction was initiated with 3 min of denaturalization at
94°C, followed by five cycles of amplification, each consisting
of 45 s at 94°C, 45 s at 68°C and 45 s at 72°C, and 36 cycles
consisting of 45 s at 94°C, 45 s at 64°C and 45 s at 72°C in an
Eppendorff cycler and a final cycle of 10 min at 72°C. We
analysed the PCR product in a 1% agarose gel stained with
ethidium bromide. Positive and negative T. cruzi blood
samples were used as internal controls of PCR. This PCR
protocol has a 0·1% sensitivity of kDNA after hybridization
with a specific probe which corresponds to one intact para-
site, or 0·01% of the T. cruzi DNA fragment circulating in the
blood or tissue from an infected host.
TNF-a mRNA expression
Hearts, removed after infliximab treatment, were stored in
liquid nitrogen until use. RNA was extracted from homog-
enized hearts with TRizol (Gibco, New York, USA) following
instructions given by the suppliers. Two micrograms of total
RNA were reverse-transcribed to first-strand cDNA by stan-
dard procedures using 50 mg/ml oligodeoxythymidylic acid
(oligo-dT) anchor primers, 5 mM deoxyribonucleoside
triphosphate (dNTP) mixture, 1 mM dithiothreitol (DTT),
50 U RNAsaOut (Gibco) and 200 U reverse transcriptase
(SuperScript II–RNAsa H; Gibco) in the buffer supplied.
The room temperature mixture was amplified in a conven-
tional PCR procedure using 4 mM MgCl2, 5 mM dNTPs,
10 pmol each oligonucleotide and 1 U Taq DNA polymerase
(Gibco) in the buffer supplied. The following primers
were used for amplification: TNF-a forward primer
5′-ATGAGCACAGAAAGCATGATC-3′ and reverse primer
5′-CAGAGCAATGACTCCAAAGTA-3′; b-actin forward
primer 5′-CGTGACATCAAAGAGAAGCTGGTGC-3′ and
reverse primer 5′-GCTCAGGAG-GAGCAATGATCTTGAT-
3′ (Operon). Reactions were performed in an Eppendorf
thermal cycler, with the cycling parameters consisting of
94°C for 1 min, 60°C for 1 min and 72°C for 2 min with a
final extension step of 10 min at 72°C for 35 cycles. The size
of amplicons was 700 bp for TNF-a and 600 bp for b-actin.
PCR products were separated on a 1·5% agarose gel and
visualized with ethidium bromide staining. Estimation of
TNF-a transcripts expression levels was performed by stan-
dardization with internal control of b-actin, using a densi-
tometric scanning video camera and gelpro 32 analysis
program.
Antibody responses
Blood samples were collected before and after treatment
with the TNF-a blocker and allowed to clot, with the sera
being stored at -20°C. Individual serum was analysed in
duplicate for specific IgM and total IgG using a commercial
antibody capture enzyme-linked immunosorbent assay
(ELISA), coated with recombinant T. cruzi antigens
(Chagatest recombinant 3·0; Wiener Laboratories, Rosario,
Argentina) adapted for the detection of rat antibodies, as
performed previously [25].
Histopathology
Hearts, skeletal muscles, subcutaneous lymph nodes, spleens
and thymuses were removed after infliximab or control
treatment and fixed in buffered formalin for histopathology.
For hearts, five paraffin-embedded 5 mm sections of each
animal were stained with haematoxylin and eosin for evalu-
ation of inflammatory foci, tissue parasitism, myocarditis
and fibrosis. Foci of myocarditis were classified as shown
previously [26]. Briefly, normal tissue (score 0); mild foci:
slight infiltration with damage of one or two myocardial
fibres (score 1); moderate-sized foci: aggregated infiltrates
compromising three to five muscle fibres (score 2); and
intense foci: heavy accumulation of mononuclear cells with
destruction of more than five muscle fibres (score 3). In this
manner a rat showing three foci of chronic myocarditis (two
mild, one moderate) had a score of 4. Sections from each
organ were examined by an experienced pathologist blinded
to the study groups.
Immunohistochemistry
Heart tissues were analysed for the surface phenotype of
inflammatory cells. Serial 5–7 mm-thick sections of the heart
were prepared, fixed in cold acetone and subjected to indirect
immunoperoxidase staining. To identify the inflammatory
cells, mouse monoclonal anti-rat antibodies (anti-CD4, CD8
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and ED1 – a marker for inflammatory macrophages – from
Serotec, Oxford, UK) and peroxidase labelled secondary
antibodies (Sigma) were used. In addition, the immune reac-
tion was controlled by omitting primary antibodies (nega-
tive control) and by using the full procedure on spleen
sections (positive control). The material was counterstained
with Mayer’s haematoxylin. Slides were examined using a
light microscope (Zeiss, Germany). The stained cells were
identified by a partial or complete dark-coloured ring out-
lining their cell membrane. Cell counts were acquired by
counting the total number of positively stained cells in five
non-contiguous sections for each animal and analysing 50
microscopic fields in each section.
Cytokine assays and nitrite evaluation
Serum cytokines were measured by specific two-site ELISA
according to the manufacturer’s specifications. ELISA kits for
TNF-a (limit of detection 12·5 pg/ml) were purchased from
R&D (Minneapolis, MN, USA) or Pharmingen (San Diego,
CA, USA) in the case of IL-10 (limit of detection 15 pg/ml)
and IFN-g (limit of detection 15 pg/ml). All samples were
processed individually and assayed in duplicate, with plates
being read at 450 nm.NO production was estimated by serum
nitrite measurement, as described previously [10].
Data and statistical analysis
Statistical comparisons among groups were performed by
Kruskal–Wallis test followed by the Mann–Whitney U-test;
c2 and Fisher’s exact tests were used to analyse categorical
differences. Statistical significance was set at P < 0·05.
Results
Infliximab treatment modifies the features of acute
T. cruzi infection and mortality after LPS inoculation
in rats
First, we analysed infliximab bioactivity in ‘l’ rats. Antibody
capacity to bind and neutralize rat TNF-a was evidenced in
acutely infected young rats receiving infliximab (Tc +
infliximab). This group showed a significantly increased
number of blood-circulating parasites after 10 days p.i. than
their physiological saline-treated counterparts [parasites/ml,
mean standard error of the mean (s.e.m.), n = 5;
Tc + infliximab = 630 292; Tc = 120 69; P < 0·05].
Further studies in suckling rats subjected to lethal doses of
LPS and treated in parallel with infliximab showed 33%
survival after challenge compared with their counterparts
[(survival mice/total mice); LPS group = 0/12; LPS +
infliximab group = 4/12; P < 0·05]. Both set of results are
representative of two experimental rounds each.
Anti-TNF-a treatment during chagasic chronic
phase did not produce a noticeable parasite
re-emergence
The possibility of reactivation of Chagas’ disease during
infliximab treatment in chronic infected rats was evaluated
by different approaches: (1) detection of trypomastigote
forms by direct examination of peripheral blood, blood
transference to highly susceptible newborn mice and xeno-
diagnosis; (2) search for amastigote forms in tissues of dif-
ferent organs by direct microscopy; and (3) molecular
detection of kDNA and in blood and heart tissue.
Upon challenge with 1 ¥ 106 parasites of the Tulahuén
strain of T. cruzi, all male ‘l’ rats display detectable parasites
in circulation until 28 days p.i.; that is, when trypomastigote
clearance is produced and the indeterminate phase ensues.
All animals survived up to 120 days p.i., the time of killing,
and this trend was not modified by anti-TNF-a administra-
tion during the chronic phase. No circulating parasites were
observed during chronic phase before infliximab treatment
(90 days p.i., data not shown) and following its termination
(120 days p.i., Table 1), with xenodiagnoses also negative
in all infected animals, independently of the treatment
(Table 1). In contrast, kDNA in blood and heart tissue was
detected pre- and post-infliximab administration, suggesting
a very low but persistent infection (Fig. 1). Moreover, no
pathological alterations, such as splenomegaly, lymph node
enlargement or thymus atrophy, were seen in infected rats
Table 1. Studies on the presence of bloodstream forms of Trypanosoma cruzi or T. cruzi kDNA during acute and chronic infection.
Treatment Tc Tc + infliximab†
Phase Acute Chronic Acute Chronic
Days p.i. 10 120 10 120
Test:
Direct blood observation (+) 100% (-) (+) 100% (-)
Xenodiagnosis (-) (-)
Inoculation into newborn mice (-) (-)
PCR kDNA (blood) (+) 100% (+) 30% (+) 100% (+) 35%
PCR kDNA (heart) (+) 100% (+) 60 % (+) 100% (+) 65%
Data are represented as positive (+) plus the percentage, or negative (-), of each analysed parameter of six to nine rats/group. A representative
experiment of two independent rounds. †Treatment with infliximab was applied only during chronic infection. Search of T. cruzi during acute phase
[day 10 post-infection (p.i.)] was made solely as control of infection. PCR, polymerase chain reaction.
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given infliximab treatment. A search for the presence of
amastigote in diverse tissues was not successful.
Infliximab treatment did not modify T. cruzi-specific
antibody levels
Because a reactivated infection may co-exist with changes in
the T. cruzi-specific antibody levels, we also measured the
specific humoral immune response (IgG and IgM) following
anti-TNF-a treatment (120 days p.i.). As shown in Fig. 2,
detectable amounts of specific IgG were seen in both infected
groups (P < 0·001 compared to their non-infected counter-
parts), with comparisons between Tc + infliximab and Tc
animals being insignificant [P = not significant (n.s.)]. While
IgM levels were lower and became negative in a >1/20 dilu-
tion, antibodies were present in 90% of infected rats
(P < 0·05 in comparison to non-infected groups), with no
significant differences between the two infected groups.
Infliximab treatment increased circulating IL-10 levels
and diminished cardiac TNF-a mRNA
Cytokine serum levels after anti-TNF-a administration (120
days p.i.) are shown in Table 2. IFN-g levels were non-
detectable during chronic phase, regardless of treatment.
Moreover, TNF-a blocking did not affect levels of
NO-derived metabolites in sera. In contrast, increased levels
of IL-10 levels were observed in infected and infliximab-
treated rats when compared to the infected group undergo-
ing no treatment. At the same time no detectable amounts of
systemic TNF-a were seen in any of the study groups. In line
with previous studies [26], serum TNF-a was detectable
only during the early acute phase (pg/ml, Tc: 142 23, Co:
non-detectable, n = 12/group, day 10 p.i.), with no measur-
able amounts of this cytokine by the time that anti-TNF
treatment was initiated. On the other hand, hearts from
infected and infliximab-treated rats had a 50% reduction in
TNF-a mRNA expression in comparison with the single
infected group (Fig. 3). No expression of TNF-a mRNA was
seen in either of the non-infected groups.
TNF-a neutralizing antibodies reduce heart lesions
during chronic infection
Because probable T. cruzi reactivation following anti-TNF-a
treatment may favour tissue damage, microscopic studies in
myocardial samples were also carried out. Heart histological
analysis from both 120-day infected groups revealed no
parasite nests in cardiocytes. The extent of myocarditis was
determined as the percentage of normal, mild, moderate or
MWM (+)        Co Tc Tc+
1         2       3      4       5       6      7        8     9     10     11    12
kDNA 330 bp
M WM 500 bp
Infliximab  Infliximab
Fig. 1. Detection of kDNA in chronic infected heart tissues.
Representative agarose gel electrophoresis results for kDNA by heart
tissue homogenates from rats after infliximab treatment (120 days
post-infection) analysed by polymerase chain reaction. Lane 1:
molecular weight marker [MWM 500 base pairs (bp) ladder]; lane 2:
heart tissue extracted from a rat with acute infection; lanes 3 and 4:
heart tissue from non-infected and physiological saline-treated rats;
lanes 5–7: heart tissue from chronic infected rats; lanes 8 and 9: heart
tissue from non-infected but infliximab-treated rats; lanes 10–12:
heart tissue from infected and infliximab-treated rats. Arrow indicates
MWM and Trypanosoma cruzi-specific products of 330 bp. Each line is
a sample of a single animal.
Table 2. Serum cytokines in chronically infected rats following anti-tumour necrosis factor (TNF)-a treatment.
Serum mediator Co Infliximab Tc Tc + infliximab
TNF-a (pg/ml) n.d. n.d. n.d. n.d.
IFN-g (pg/ml) n.d. n.d. n.d. n.d.
IL-10 (pg/ml) n.d. n.d. 23 8 44 12*
Total nitrite (nM) 46 17 16 15 67 24** 81 32**
*P < 0·05 Tc + infliximab versus Tc. **P < 0·05 versus the respective control group. Values represent mean standard error of the mean of six
to nine rats/group. Samples were taken after 120 days post-infection. A representative experiment of two independent rounds. IFN, interferon;
IL, interleukin; n.d., non-detectable.
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Fig. 2. Immunoglobulin (Ig)-specific levels after infliximab therapy.
IgM and IgG Trypanosoma cruzi-specific levels were evaluated by
enzyme-linked immunosorbent assay after infliximab treatment
(120 days post-infection). Detectable amounts of specific IgM (1/20)
and IgG (1/200 dilution) were seen in both groups of chronically
infected rats, without significant differences between them. Tc and
Tc + infliximab groups significantly different from their non-infected
counterparts (P < 0·001, both immunoglobulin isotypes). Values
represent means standard error of the mean of optical density unit
of six to nine rats/group. A representative experiment of two
independent rounds.
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intense damage observed in each group. Among the infected
and non-treated rats an easily noticeable myocarditis, with
multiple inflammatory foci of 34% intense magnitude, was
seen. In contrast, ameliorated lesions were seen in the
infected group given infliximab, with only 8·3% of rats
showing intense myocarditis (Tc versus Tc + infliximab;
P < 0·05, Fig. 4, upper panels). As seen in Table 3, the latter
group displayed a lower score of inflammatory foci com-
pared with the non-treated group (P < 0·02). Further immu-
nostaining analysis demonstrated that the reduced chronic
myocardial damage of the infected and infliximab-treated
group was associated with decreased numbers of CD4+,
CD8+ and ED1+ infiltrating cells (Table 4 and bottom panels
of Fig. 4).
Discussion
The relevance of TNF-a in acute T. cruzi infection has been
supported by studies of cytokine neutralization or in TNF
receptor knock-out mice, showing serious deficiencies in
host resistance to this protozoan [11,12,27–29]. In contrast,
evidence on the role of TNF-a during the chronic chagasic
phase is scarce, although its presence might contribute to
disease immunopathology. It is now accepted that T. cruzi
persists during the chronic period, as it can be detected spo-
radically in chronic chagasic patients [30]. As TNF-a con-
tributes to parasite control [6,7] TNF-a blocking might
favour T. cruzi reactivation, in view of the increased suscep-
tibility to diseases caused by intracellular pathogens after
anti-TNF-a therapies, i.e. tuberculosis [31], malaria [32],
toxoplasmosis [33] and leishmaniasis [34]. Our studies in
chronically infected rats given infliximab failed to detect
parasites either by direct blood examination, xenodiagnosis
or blood inoculation into highly susceptible mice, implying
that TNF-a might be less relevant for T. cruzi control during
the chronic phase. However, as tissue TNF-a mRNA after
infliximab treatment was reduced but still detected, the
question remains of whether a more prolonged blockade of
TNF-a will result in parasite reactivation. So far, cases
reported of Chagas’ reactivation have occurred in immuno-
compromised hosts such as acquired immune deficiency
syndrome (AIDS) patients, subjects undergoing chemo-
therapy or transplanted individuals [35–37]. This may imply
that T. cruzi reactivation occurs only when cell-mediated
immune response is affected profoundly, precluding an
effective anti-parasite response.
Human and experimental studies reveal considerable
amounts of anti-T. cruzi antibodies during chronic infection,
suggesting that humoral response may control circulating
parasites rapidly in case of reactivation. In this sense, our
previous study showed that parasitaemia in T. cruzi-
reinfected rats was of lesser magnitude than that seen in the
initial infection, but with abundant amounts of specific anti-
bodies [22]. Castaños-Velez et al. suggested that susceptibil-
ity to acute T. cruzi infection in TNF-R1 knock-out mice
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Fig. 3. Tumour necrosis factor (TNF)-a mRNA expression in
myocardial tissue. TNF-a mRNA expression in myocardial tissue was
evaluated by semiquantitative reverse transcription–polymerase chain
reaction after infliximab treatment (120 days post-infection). b-actin
mRNA was used to normalize TNF-a mRNA among samples. Relative
values were calculated considering TNF-a/b-actin ratio as 1 for
infected but non-treated animals. No expression of TNF-a mRNA
was seen in both non-infected groups, Normalized results correspond
to two experimental series of four to six animals/group (media of
relative value of sample corresponding to an individual
animal standard error of the mean).
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Fig. 4. Histopathology evaluation of chronic myocarditis. (a) Intense
inflammatory foci in a chronically infected rat; (b) mild inflammatory
foci observed in chronically infected and infliximab-treated rat; (c)
CD8+ cells in heart tissue of infected animals (mild foci); (d) CD8+
cells in the myocardium of chronically infected and infliximab-treated
animals (mild foci). Magnification panels 20¥. In all cases, the
respective non-infected control groups are showed in the small cages.
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might be related to a deficiency in antibody production [12].
In fact, TNF-R1 participates in lymph node structure main-
tenance, germinal centre formation and the switch and affin-
ity maturation of immunoglobulins [38,39], although these
effects seem to be mediated by lymphotoxin-alpha, which
also interacts with TNF-R1 [38]. Some authors suggest that
TNF-a blockade prevents the generation and maintenance
of adaptive immune responses by inhibiting lymphoid
hyperplasia [40]. However, there is consensus that in adult
animals, TNF-a neutralization has no apparent effect on
lymphoid structure or germinal centre formation [41]. In
our hands, anti-TNF-a treatment did not reduce anti-
T. cruzi antibodies levels, because an important humoral
response against T. cruzi was maintained in the absence of
detectable circulating parasite forms. In addition, the
absence of increased levels of specific IgM favours the view of
no reactivation, as IgM is regarded as a sign of parasite
re-emergence in chronically infected pregnant women
[42,43]. Moreover, congenital cases of Chagas’ disease are
associated with measurable maternal IgM, whereas infected
mothers not transmitting parasites during pregnancy show a
non-detectable IgM response [44].
Chronic myocardial damage in Chagas’ disease may be
promoted by the parasite and/or by the immune response
against parasite antigens or mimetic epitopes. TNF-a is
likely to contribute to the development of chronic myocardi-
tis, as it was detected in sera [15,16] and myocardial biopsies
from chronic chagasic patients [45], also related to myo-
carditis severity [46]. A consistent feature of our rat model is
the development of focal myocarditis, characterized by lym-
phocyte and monocyte infiltration, destruction of the myo-
cardial fibre and fibrosis. Treatment with TNF-a antagonist
in chronically infected rats reduced TNF-a mRNA, the
number and the severity of lesions and the presence of CD8+,
CD4+ and ED1+ inflammatory cells. Because TNF-a is
related to the ability of T cells and macrophages to migrate to
target tissues, infliximab treatment probably altered leuco-
cyte recruitment to the heart. These results agree with our
previous studies, where mice deficient in both TNF-a recep-
tors showed an absence of inflammatory infiltration and
fibre destruction in myocardial tissue, contrasting with the
severe injury observed in acutely infected wild-type mice
[26]. Nevertheless, our data are at variance with a report in
chronically infected hamsters, in which the TNF-a antago-
nist etanercept was implied in heart dysfunction, but
without variations in the severity of myocarditis [47]. Dif-
ferences in TNF-a antagonists and experimental conditions
may account for such discrepancy. While infliximab and
etanercept both neutralize the soluble form of TNF-a, inflix-
imab binds more powerfully to the membrane form of
TNF-a (mTNF) than does etanercept. Etanercept is a recom-
binant soluble receptor TNF-R2-IgG1, whereas infliximab is
a chimeric monoclonal antibody [48]. As mTNF expression
may be up-regulated on T lymphocytes activated by T. cruzi
antigens, treatment with anti-TNF-a monoclonal antibodies
may alter migratory properties of activated anti-parasite T
lymphocytes more than does etanercept. Also, etanercept can
bind and neutralize LT-a, which can be produced by
macrophages and T cells [49].
An alternative and mutually non-exclusive possibility for
decreased cellular infiltration deals with the presence of anti-
inflammatory cytokine milieu. Increased systemic levels of
IL-10 observed in infected and treated rats lend some
support to this assumption. Raised levels of IL-10 in anti-
TNF-a treated rats is in line with our previous findings of
cytokine dysregulation in TNF-Rs knock-out mice infected
with T. cruzi [28].
Infliximab therapy in humans has been reported in a
variety of off-label uses, mainly autoimmune and inflamma-
tory diseases [49]. As chronic chagasic myocarditis may be
the result of several concomitant pathogenic mechanisms,
such as immune responses to parasite antigens [50], autoim-
Table 3. Score of myocarditis severity after infliximab treatment.
Co Infliximab Tc Tc + infliximab
Score of inflammatory foci 0·6 1·2 0·5 0·2 13 5·4 5 2·6*
*P < 0·02 Tc + infliximab versus Tc. Heart samples were obtained after the treatment with the tumour necrosis factor (TNF)-a blocker (120 days
post-infection) and fixed in buffered formalin. Paraffin-embedded 5 mm sections were stained with haematoxylin and eosin (five serial sections of each
animal). A score was also calculated on the basis of the number and severity of chronic inflammatory foci: normal tissue (score 0); mild foci (score 1);
moderate-sized foci (score 2); intense foci (score 3). In this way a rat showing three foci of chronic myocarditis (two mild, one moderate) had a score
of 4. Values represent the mean standard error of the mean of 11–12 animals/group. A representative experiment of two independent rounds.
Table 4. CD4+, CD8+ and ED1+ cells in myocardial tissue after infliximab treatment (day 120 post-infection).
Co Infliximab Tc Tc + infliximab
CD4+ cells 13 (3–24) 16 (2–19) 107 (76–165) 78 (21–111)*
CD8+ cells 44 (13–73) 35 (7–45) 228 (169–334) 150 (125–197)*
ED1+ cells 15 (3–47) 12 (2–33) 148 (96–198) 94 (64–134)*
*P < 0·05 Tc + infliximab versus Tc. Fifty fields in five sections were examined for each animal. The results represent count cells as median (range)
of data from each group (six to nine rats/group). A representative experiment of two independent rounds.
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mune processes [51,52] and the inflammation accompany-
ing these responses [53], the potential effects of infliximab
on chagasic myocarditis were worthy of study.
The present results suggest that blocking TNF-a activity is
not critical for causing T. cruzi reactivation during the
chronic phase, and at the same time highlight the key role of
TNF-a in the development of T. cruzi-associated immunoin-
flammatory pathology. The findings also provide a stimulat-
ing background for assessing whether longer treatment
periods continue to be safe and beneficial, as a basic require-
ment for further human studies.
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